Acute Kidney Injury in Cancer Patients Receiving Anti-Vascular Endothelial Growth Factor Monoclonal Antibody vs Immune Checkpoint Inhibitors: a Retrospective Real-world Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 1,581
- 试验地点
- 1
- 主要终点
- accumulative incidence of sustained AKI
研究概览
简要总结
The goal of this a retrospective real-world study is to compare the AKI events in cancer patients receiving anti-vascular endothelial growth factor monoclonal antibody (AntiVEGF) vs immune checkpoint inhibitors (ICIs). The main question it aims to answer is whether the choice between AntiVEGF and ICIs affects the risks of acute kidney injury in cancer patients.
Cancer patients receiving AntiVEGF will be compared to those treated with ICIs to see if the AKI incidence is higher in patients receiving ICIs.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 20 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age >=20yr;
- •Patients must have at least one "Evaluation and Management"visit with a diagnosis of cancer within 12 months before index date (In situ biopsy will not be required, since patients may receive a diagnosis from a biopsy of metastatic site);
- •Indication to initiate AntiVEGF or ICIs
排除标准
- •Patients without valid data and less than 3 months followup;
- •Patients without baseline Scr value within 12 mon before index date;
- •Patients with combination therapy of Anti-VEGF and ICIs ;
- •Patients with chronic renal failure
研究组 & 干预措施
AntiVEGF
cancer patients receiving anti-vascular endothelial growth factor monoclonal antibody (AntiVEGF)
干预措施: AntiVEGF (Drug)
ICIs
cancer patients receiving immune checkpoint inhibitors (ICIs).
干预措施: ICIs (Drug)
结局指标
主要结局
accumulative incidence of sustained AKI
时间窗: 12 months after index date
sustained AKI will be defined as the elevation ≥1.5 times baseline sCr for ≥72hours according to the Kidney Disease Improving Global Outcomes (KDIGO) sCr criteria
次要结局
未报告次要终点
研究者
Tianxin Chen
Principal Investigator
First Affiliated Hospital of Wenzhou Medical University
